Nexa Medical Team up with Novus to Exploit the Advanced Wound Care Market that is Estimated to be Worth 13.07 Billion by 2022

The founders of Nexa Medical who have more than 50 years’ knowledge and experience of the Medical Device sector and specifically wound care, have selected Novus Investments to support them with commercialising their exciting, new and patented Mercury Platform Technology.

The technology has been specifically developed to address some of the significant unmet need in the rapidly growing Advanced Wound Care Market, which is estimated to be worth globally 13.07 billion USD by 2022.

The Novus team with its extensive knowledge and experience of the medical sector will now work with Nexa Medical to develop a strategy to deliver the successful commercialisation of the technology.

Author: Clive Gunther